The PD-L1 test assists physicians in assessing a patient's potential benefit from immunotherapy, particularly in non-small cell lung cancer (NSCLC), ga
The new prime DX® technology for molecular tumor profiling is compatible with both FFET and PLASMA and in combination (COMBO)for more holistic analysi
The MyWES® test utilizes Whole Exome Sequencing (WES) to conduct a comprehensive analysis of more than 20,000 genes for the identification and diagnos
In order to find patients who may benefit from PARP inhibitor treatment, the BRCA Somatic test looks for both hereditary and non-inherited mutations in
This assay improves the prediction of a patient’s response to immunotherapy across various cancer types and assists the physician in selecting the mo
